Skip to main content

Advertisement

SpringerLink
Log in

Diabetes and Sexual Function

  • Preclinical and Psychophysiology (J Pfaus and L Marson, Section Editors)
  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript

Abstract

Diabetes mellitus (DM) is a global health issue and a major risk factor for sexual dysfunction. Diabetic patients are at an increased risk for erectile dysfunction (ED), ejaculatory disorders, and hypogonadism. ED in these patients results from a multitude of pathophysiological mechanisms that culminate in vascular, neurogenic, and myogenic damage. Furthermore, these patients are often difficult to treat with current pharmacologic therapies. Ejaculatory disorders can be problematic, often requiring invasive modalities for those patients who wish to procreate. Finally, hypogonadism remains a topic of great debate in the diabetic population and general population alike. Its relation to the development of low sexual drive and even DM, itself, requires further investigation. Overall, the complex pathophysiology of this condition makes it difficult to develop clinical treatments tailored specifically for diabetic patients. As our understanding of diabetic ED progresses, the development of novel and effective treatment strategies will evolve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol. 2012;771:35–41. This study underscores the reality that diabetes is and will increasingly continue to be a major health concern throughout the world.

    PubMed  Google Scholar 

  2. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. England: 2010 Elsevier Ltd;375:2010. p. 2215–22.

  3. O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362–425.

    Article  PubMed  Google Scholar 

  4. Isidro ML. Sexual dysfunction in men with type 2 diabetes. Postgrad Med J. 2012;88:152–9.

    Article  CAS  PubMed  Google Scholar 

  5. El-Sakka AI. Premature ejaculation in non-insulin-dependent diabetic patients. Int J Androl. 2003;26:329–34.

    Article  PubMed  Google Scholar 

  6. Malavige LS, Jayaratne SD, Kathriarachchi ST, Sivayogan S, Fernando DJ, Levy JC. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med. 2008;5:2125–34.

    Article  PubMed  Google Scholar 

  7. Hijazi RA, Betancourt-Albrecht M, Cunningham GR. Gonadal and erectile dysfunction in diabetics. Med Clin North Am. 2004;88:933–45. xi.

    Article  CAS  PubMed  Google Scholar 

  8. Rutte A, Welschen LM, Van Splunter MM, Schalkwijk AA, De Vries L, Snoek FJ, et al. Type 2 diabetes patients’ needs and preferences for care concerning sexual problems: a cross-sectional survey and qualitative interviews. J Sex Marital Ther. 2015.

  9. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002;25(2):284–91.

    Article  PubMed  Google Scholar 

  10. Helgason AR, Adolfsson J, Dickman P, Arver S, Fredrikson M, Gothberg M, et al. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. Age Ageing. 1996;25(4):285–91.

    Article  CAS  PubMed  Google Scholar 

  11. Masters M, Johnson V. Human Sexual Response. Boston: Little Brown and Co.; 1966.

    Google Scholar 

  12. Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6:1506–33.

    Article  CAS  PubMed  Google Scholar 

  13. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005;32(4):379–95. v.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gil-Vernet Jr JM, Alvarez-Vijande R, Gil-Vernet A, Gil-Vernet JM. Ejaculation in men: a dynamic endorectal ultrasonographical study. Br J Urol. 1994;73(4):442–8.

    Article  PubMed  Google Scholar 

  15. Bhasin S, Basson R. Sexual dysfunction in men and women. 2011. In: Williams Textbook of Endocrinology [Internet]. 12. [778–816]

  16. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology. 1997;50:1016–26.

    Article  CAS  PubMed  Google Scholar 

  17. Folkerts G, Kloek J, Muijsers RB, Nijkamp FP. Reactive nitrogen and oxygen species in airway inflammation. Eur J Pharmacol. 2001;429:251–62.

    Article  CAS  PubMed  Google Scholar 

  18. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20(10):2175–83.

    Article  CAS  PubMed  Google Scholar 

  19. Musicki B, Palese MA, Crone JK, Burnett AL. Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection. Biol Reprod. 2004;70:282–9.

    Article  CAS  PubMed  Google Scholar 

  20. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. Pharmacol Ther. 2006;111:400–23.

    Article  CAS  PubMed  Google Scholar 

  21. Mills TM, Pollock DM, Lewis RW, Branam HS, Wingard CJ. Endothelin-1-induced vasoconstriction is inhibited during erection in rats. Am J Physiol Regul Integr Comp Physiol. 2001;281(2):R476–83.

    CAS  PubMed  Google Scholar 

  22. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22(24):8467–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2004;101:9121–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6:1232–47.

    Article  PubMed  Google Scholar 

  25. El-Sakka AI, Tayeb KA. Vascular impairment of erection in patients with diabetes and Peyronie’s disease: is that accumulative? J Sex Med. 2009;6:1736–42.

    Article  PubMed  Google Scholar 

  26. Yaman O, Akand M, Gursoy A, Erdogan MF, Anafarta K. The effect of diabetes mellitus treatment and good glycemic control on the erectile function in men with diabetes mellitus-induced erectile dysfunction: a pilot study. J Sex Med. 2006;3:344–8.

    Article  PubMed  Google Scholar 

  27. Hecht MJ, Neundorfer B, Kiesewetter F, Hilz MJ. Neuropathy is a major contributing factor to diabetic erectile dysfunction. Neurol Res. 2001;23(6):651–4.

    Article  CAS  PubMed  Google Scholar 

  28. Wen Y, Skidmore JC, Porter-Turner MM, Rea CA, Khokher MA, Singh BM. Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab. 2002;4:305–8.

    Article  CAS  PubMed  Google Scholar 

  29. Sezen SF, Lagoda G, Musicki B, Burnett AL. Hydroxyl fasudil, an inhibitor of Rho signaling, improves erectile function in diabetic rats: a role for neuronal ROCK. J Sex Med. 2014;11(9):2164–71. This study evaluates the ROCK pathway as a potential target for inhibition to treat erectile dysfunction in diabetic patients.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171:1797–803.

    Article  PubMed  Google Scholar 

  31. Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med. 2014;11(7):1626–35.

    Article  CAS  PubMed  Google Scholar 

  32. Chen Y, Cui S, Lin H, Xu Z, Zhu W, Shi L, et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res. 2012;24:217–20.

    Article  CAS  PubMed  Google Scholar 

  33. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159–64.

    Article  PubMed  Google Scholar 

  34. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–83.

    Article  CAS  PubMed  Google Scholar 

  35. Behrend L, Vibe-Petersen J, Perrild H. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res. 2005;17(3):264–9.

    Article  CAS  PubMed  Google Scholar 

  36. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol. 2007;52(6):1768–74.

    Article  CAS  PubMed  Google Scholar 

  37. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008;25(2):138–46.

    Article  CAS  PubMed  Google Scholar 

  38. Deyoung L, Chung E, Kovac JR, Romano W, Brock GB. Daily use of sildenafil improves endothelial function in men with type 2 diabetes. J Androl. 2012;33(2):176–80.

    Article  CAS  PubMed  Google Scholar 

  39. Goldstein I, Jones LA, Belkoff LH, Karlin GS, Bowden CH, Peterson CA, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc. 2012;87(9):843–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hamidi Madani A, Asadolahzade A, Mokhtari G, Shahrokhi Damavand R, Farzan A, Esmaeili S. Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. J Sex Med. 2013;10(4):1146–50.

    Article  PubMed  Google Scholar 

  41. Gaunay G, Nagler HM, Stember DS. Reproductive sequelae of diabetes in male patients. Endocrinol Metab Clin North Am. 2013;42(4):899–914.

    Article  PubMed  Google Scholar 

  42. Chen J, Sofer M, Kaver I, Matzkin H, Greenstein A. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol. 2004;171:292–5. This article discusses established treatments for diabetic ED and provides an update of both medical and surgical treatment approaches.

    Article  PubMed  Google Scholar 

  43. Canguven O, Bailen J, Fredriksson W, Bock D, Burnett AL. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med. 2009;6:2561–7.

    Article  PubMed  Google Scholar 

  44. Flynn T, Guest J. Intracorporeal and transurethral application of alprostadil: a review of the literature. Int J Impotence Res; 1998. p. S47.

  45. Redrow GP, Thompson CM, Wang R. Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. Expert Opin Pharmacother. 2014;15(13):1827–36.

    Article  PubMed  Google Scholar 

  46. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl. 2006;8(6):675–84.

    Article  PubMed  Google Scholar 

  47. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334(14):873–7.

    Article  CAS  PubMed  Google Scholar 

  48. Tsai YS, Lin JS, Lin YM. Safety and efficacy of alprostadil sterile powder (S. Po., CAVERJECT) in diabetic patients with erectile dysfunction. Eur Urol. 2000;38:177–83.

    Article  CAS  PubMed  Google Scholar 

  49. Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs. Eur Urol. 2001;40:398–402. discussion 3.

    Article  CAS  PubMed  Google Scholar 

  50. Plekhanov A, Zhivovo A, Goryachew L. Comparative complication rate after alprostadil intracavernous pharmaco-therapy for erectile dysfunction in diabetes mellitus vs. non-diabetic patients. Int J Impot Res; 1998. p. S50.

  51. Carson CC. Penile prosthesis implantation: surgical implants in the era of oral medication. Urol Clin North Am. 2005;32:503–9. vii.

    Article  PubMed  Google Scholar 

  52. Mulhall JP, Ahmed A, Branch J, Parker M. Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol. 2003;169:1429–33.

    Article  PubMed  Google Scholar 

  53. Hatzimouratidis K, Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014;14(11):545.

    Article  PubMed  Google Scholar 

  54. Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res. 2001;13(6):326–8.

    Article  CAS  PubMed  Google Scholar 

  55. Wilson SK, Carson CC, Cleves MA, Delk 2nd JR. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol. 1998;159:1537–9. discussion 9–40.

    Article  CAS  PubMed  Google Scholar 

  56. Carson 3rd CC, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol. 2011;185:614–8. This study demonstrates that retrograde ejaculation is a frequent condition in men with DM.

    Article  PubMed  Google Scholar 

  57. Dunsmuir WD, Holmes SA. The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus. Diabet Med. 1996;13(8):700–8.

    Article  CAS  PubMed  Google Scholar 

  58. Bellastella G, Maiorino MI, Olita L, Della Volpe E, Giugliano D, Esposito K. Premature ejaculation is associated with glycemic control in Type 1 diabetes. J sexual Med. 2015;12(1):93–9.

    Article  CAS  Google Scholar 

  59. Fedder J, Kaspersen MD, Brandslund I, Hojgaard A. Retrograde ejaculation and sexual dysfunction in men with diabetes mellitus: a prospective, controlled study. Andrology. 2013;1(4):602–6.

    Article  CAS  PubMed  Google Scholar 

  60. Sexton WJ, Jarow JP. Effect of diabetes mellitus upon male reproductive function. Urology. 1997;49:508–13.

    Article  CAS  PubMed  Google Scholar 

  61. La Vignera S, Condorelli RA, Di Mauro M, D’Agata R, Vicari E, Calogero AE. Seminal vesicles and diabetic neuropathy: ultrasound evaluation. J Androl. 2011;32:478–83.

    Article  PubMed  Google Scholar 

  62. Arafa M, El Tabie O. Medical treatment of retrograde ejaculation in diabetic patients: a hope for spontaneous pregnancy. J Sex Med. 2008;5:194–8.

    Article  CAS  PubMed  Google Scholar 

  63. Ohl DA, Quallich SA, Sonksen J, Brackett NL, Lynne CM. Anejaculation and retrograde ejaculation. Urol Clin North Am. 2008;35:211–20. viii.

    Article  PubMed  Google Scholar 

  64. Fode M, Krogh-Jespersen S, Brackett NL, Ohl DA, Lynne CM, Sonksen J. Male sexual dysfunction and infertility associated with neurological disorders. Asian J Androl. 2012;14:61–8.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1992;117(10):807–11.

    Article  CAS  PubMed  Google Scholar 

  66. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care. 2000;23(7):912–8.

    Article  CAS  PubMed  Google Scholar 

  67. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006;18:190–7.

    Article  CAS  PubMed  Google Scholar 

  68. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S. Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male. 2008;11:107–17.

    Article  CAS  PubMed  Google Scholar 

  69. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;143(9):889–97.

    Article  CAS  PubMed  Google Scholar 

  70. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007;30:234–8.

    Article  CAS  PubMed  Google Scholar 

  71. Rabijewski M, Papierska L, Zgliczynski W, Piatkiewicz P. The incidence of hypogonadotropic hypogonadism in type 2 diabetic men in Polish population. Biomed Res Int. 2013;2013:767496.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J Clin Endocrinol Metab. 1981;53(4):828–32.

    Article  CAS  PubMed  Google Scholar 

  73. Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt—a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52:49–51.

    Article  CAS  PubMed  Google Scholar 

  74. Strain GW, Zumoff B, Miller LK, Rosner W, Levit C, Kalin M, et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J Clin Endocrinol Metab. 1988;66(5):1019–23.

    Article  CAS  PubMed  Google Scholar 

  75. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32.

    Article  CAS  PubMed  Google Scholar 

  76. Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M. Plasma leptin and insulin relationships in obese and nonobese humans. Diabetes. 1996;45(5):695–8.

    Article  CAS  PubMed  Google Scholar 

  77. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84(10):3673–80.

    CAS  PubMed  Google Scholar 

  78. Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care. 2006;29:2289–94.

    Article  CAS  PubMed  Google Scholar 

  79. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004;25:4–7.

    Article  CAS  PubMed  Google Scholar 

  80. Burcelin R, Thorens B, Glauser M, Gaillard RC, Pralong FP. Gonadotropin-releasing hormone secretion from hypothalamic neurons: stimulation by insulin and potentiation by leptin. Endocrinology. 2003;144:4484–91. This study evaluated the effects of testosterone replacement therapy on insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2 diabetes and/or metabolic syndrome.

    Article  CAS  PubMed  Google Scholar 

  81. Ballester J, Munoz MC, Dominguez J, Rigau T, Guinovart JJ, Rodriguez-Gil JE. Insulin-dependent diabetes affects testicular function by FSH- and LH-linked mechanisms. J Androl. 2004;25:706–19. This study aimed to determine the effect of testosterone replacement on sexual function, mood and quality of life in type 2 diabetics.

    Article  CAS  PubMed  Google Scholar 

  82. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008;159:507–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10(6):1612–27.

    Article  CAS  PubMed  Google Scholar 

  85. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011;8(11):3204–13.

    Article  CAS  PubMed  Google Scholar 

  86. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11(6):1567–76.

    Article  CAS  PubMed  Google Scholar 

  87. Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, Grossmann M. Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014;99(10):3821–8.

    Article  CAS  PubMed  Google Scholar 

  88. Berman JR. Physiology of female sexual function and dysfunction. Int J Impot Res. 2005;17 Suppl 1:S44–51.

    Article  PubMed  Google Scholar 

  89. Bargiota A, Dimitropoulos K, Tzortzis V, Koukoulis GN. Sexual dysfunction in diabetic women. Hormones (Athens). 2011;10(3):196–206.

    Article  Google Scholar 

  90. Kim NN, Stankovic M, Cushman TT, Goldstein I, Munarriz R, Traish AM. Streptozotocin-induced diabetes in the rat is associated with changes in vaginal hemodynamics, morphology and biochemical markers. BMC Physiol. 2006;6:4.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Enzlin P, Rosen R, Wiegel M, Brown J, Wessells H, Gatcomb P, et al. Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort. Diabetes Care. 2009;32:780–5.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Giraldi A, Kristensen E. Sexual dysfunction in women with diabetes mellitus. J Sex Res. 2010;47:199–211. The study evaluates the impact of diabetes on female sexuality and highlights differences between sexuality in the context of type 1 and type 2 diabetes mellitus.

    Article  PubMed  Google Scholar 

  93. Althof SE. What’s new in sex therapy (CME). J Sex Med. 2010;7:5–13. quiz 4–5.

    Article  PubMed  Google Scholar 

  94. Wilson SK, Delk 2nd JR, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med. 2001;4(2):54–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Urology, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-42, New Orleans, LA, 70112, USA

    Taylor C. Peak & Wayne J. G. Hellstrom

  2. Department of Pharmacology, School of Pharmacy, Ankara University, Ankara, Turkey

    Serap Gur

Authors
  1. Taylor C. Peak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serap Gur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wayne J. G. Hellstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wayne J. G. Hellstrom.

Ethics declarations

Conflicts of Interest

Taylor C. Peak and Serap Gur declare that they have no conflicts of interest. Wayne J.G. Hellstrom reports personal fees from Abbvie, Allergan, AMS, Antares, Apricus, Astellas, Auxilium, Coloplast, Endo, Lilly, Menerini, Pfizer, Promescent, and Repros; others from Auxilum, Coloplast, Endo, NERI, NIH, and Theralogix; and grants from Auxilum, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection Preclinical and Psychophysiology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peak, T.C., Gur, S. & Hellstrom, W.J.G. Diabetes and Sexual Function. Curr Sex Health Rep 8, 9–18 (2016). https://doi.org/10.1007/s11930-016-0065-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11930-016-0065-2

Keywords

Search

Navigation